Clinical Utility

Not all prostate cancers are the same - some are aggressive and require treatment with surgery or radiation therapy. However, many are lower risk and can be managed with regular doctor visits and monitoring called active surveillance - delaying or completely avoiding treatments like surgery or radiation.

Oncotype DX GPS will help understand the patient’s individualized risk to better inform decisions about what happens next; active surveillance or treatment.

The Oncotype DX GPS gives individualized information about how aggressive the cancer is - information that’s not available from any other traditional test or tool. It:

  • Analyzes the unique biology of the tumor.
  • Examines gene activity inside the prostate tumor, and the role they play in the patients’ health - a science known as genomics.
  • Provides a more specific and individualized assessment of whether the tumor is more or less aggressive than the biopsy results suggest.

For more information click here.


Genomic Health, Inc. (now trading as "Exact Sciences")
Oncotype DX Breast Recurrence Score, Oncotype DX and Recurrence Score are registered trademarks of Genomic Health, Inc.
Exact Sciences is a trademark or registered trademark of Exact Sciences Corporation. ©2020 Genomic Health, Inc. All rights reserved.